Breast Cancer Therapeutics Market Forecasts to 2030 - Global Analysis By Type (Hormonal Therapy, Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies), Cancer Type, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Breast Cancer Therapeutics Market is accounted for $29.1 billion in 2023 and is expected to reach $54.3 billion by 2030 growing at a CAGR of 9.3% during the forecast period. Breast cancer therapeutics refers to the various treatments and interventions designed to manage, treat, or cure breast cancer. These therapeutics encompass a wide range of approaches, including surgery, chemotherapy, radiation therapy, targeted therapy, hormone therapy, immunotherapy, and newer emerging treatments like precision medicine and gene therapy. Therapeutic approaches often vary based on the stage of the cancer, its specific characteristics, and the individual patient's health and preferences.

According to the Breast Cancer Organizations statistics, as of January 2022, breast cancer affects more than 3.8 million American women. The statistics indicate that in the year 2022, around 30% of newly diagnosed cancers among women are estimated to be breast cancer cases.

Market Dynamics:

Driver:

Rising incidence of breast cancer

The increasing prevalence of breast cancer globally prompts greater demand for therapeutic options, spurring research and development efforts. Emerging technologies offer more targeted therapies, improving efficacy and reducing side effects. The growing awareness of early detection emphasizes the need for comprehensive treatment solutions, creating a conducive environment for market expansion. This surge in demand encourages competitive pricing strategies and fosters collaborations for enhanced patient care, propelling the market forward.

Restraint:

Adverse effects of therapeutics

Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth. In cases of severe adverse reactions, the patient may not be able to use that particular drug and may have to move toward other types of therapeutics. Side effects of treatments can be severe and impact the patient's quality of life.

Opportunity:

Expanding geriatric population

With an aging population worldwide, there's a higher incidence of cancer, including breast cancer, leading to a greater demand for therapeutic options. With advanced age being a primary risk factor for breast cancer, the growing demographic of older individuals creates a larger pool of potential patients. Additionally, increased awareness and improved screening methods within this population offer opportunities for early detection and intervention, fostering better treatment outcomes and market expansion.

Threat:

High cost of therapies

Many advanced breast cancer treatments are expensive, limiting access for patients without adequate insurance coverage or financial resources. Affordability issues lead to unequal access to innovative medications, impacting treatment efficacy and patient outcomes. High expenses also burden healthcare systems, constraining resources and potentially limiting research and development of newer, more accessible therapies. These cost barriers hinder the growth of the market.

Covid-19 Impact:

The coronavirus outbreak has disrupted the global economy, inflicting economic burden and financial adversities. Many sectors have witnessed drastic transition including the healthcare sector. Hospital admissions regarding COVID-19 affected patients were prioritized, with other medical procedures postponed. The pandemic has had a limited impact on this global market as this treatment is considered a life-saving treatment for several patients.

The targeted therapy segment is expected to be the largest during the forecast period

The targeted therapy segment is expected to be the largest during the forecast period. Targeted therapy in breast cancer offers precise treatment, attacking specific molecules crucial for cancer growth while sparing healthy cells. It enhances efficacy with reduced side effects compared to traditional treatments, improving patient outcomes. Their ability to prevent cancer's progression by pinpointing distinct pathways amplifies treatment effectiveness, promising better survival rates and a higher quality of life for patients.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Hospital pharmacies play a pivotal role in breast cancer therapeutics by ensuring timely access to specialized medications, optimizing drug regimens, and providing personalized care. They facilitate seamless coordination between healthcare teams, ensuring accurate dosing and monitoring of treatments, thereby enhancing patient outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to government initiatives, and the presence of key pharmaceutical companies. The region is dynamic, with ongoing research, clinical trials, and collaborations between pharmaceutical companies and research institutions driving innovation. It's also supported by strong healthcare infrastructure and favorable reimbursement policies, allowing patients access to advanced treatments.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors, including increasing awareness, advancements in technology and improved access to healthcare facilities. There's also a growing trend toward personalized medicine, where treatments are tailored based on the specific characteristics of the tumor. The adoption of advanced diagnostic tools and treatment modalities has significantly improved patient outcomes.

Key players in the market

Some of the key players in Breast Cancer Therapeutics market include Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Novartis AG, Perkin Elmer Inc., Pfizer Inc., Puma Biotechnology Inc., NanoString Technologies Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., AbbVie Inc., Amgen Inc., Bristol Myers Squibb and Clovis Oncology.

Key Developments:

In February 2023, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Trodelvy to treat adult patients with inoperable locally advanced or metastatic breast cancer. This approval anticipates enhancing the available treatment choices and likely leading to improved outcomes for patients suffering from breast cancer.

In November 2022, Eli Lilly and Company launched the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI), in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, HER2 negative, node-positive EBC at high risk of recurrence.

Therapies Covered:

• Hormonal Therapy
• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Other Therapies

Cancer Types Covered:

• HER2+
• Hormone Receptor

Distribution Channels Covered:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

End Users Covered:

• Research Institutions
• Diagnostic Centers
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances